Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM) and remains the leading cause of vision loss worldwide in the working-age population.[@bib1]^--^[@bib3] Therapeutic intervention is currently targeted toward treating complications resulting from irreversible structural changes in retinal vasculature. Early detection of the vascular abnormalities in diabetic eyes could provide timely recognition and management of patients at high risk of development of DR and progression.[@bib4] The pathogenesis of DR is primarily attributed to vascular abnormalities in the retina.[@bib5] Since the choroid is a vascular layer that supplies the outer retina, the potential effects of choroidal blood flow on the pathophysiology of DR have attracted increasing attention.[@bib6] A few studies using indocyanine green angiography (ICGA) have shown choroidal abnormalities in eyes with DR.[@bib7]^--^[@bib9] Selective filling of the choriocapillaris (CC) on ICGA is speculated to represent the existence of early diabetic choroidopathy.[@bib9] However, due to insufficient lateral resolution and lack of depth-resolved information of ICGA,[@bib10] the delineation and quantification of CC flow in vivo are not attainable.

Optical coherence tomography (OCT) is a noninvasive imaging modality that has been widely applied in ophthalmic imaging.[@bib11] With the development of OCT angiography (OCTA), blood flow can now be visualized in vivo with depth-resolved capability of the retinal and choroidal circulation in a rapid fashion.[@bib12] While retinal vasculature imaging using OCTA is well documented in those with diabetic retinopathy, few studies have investigated blood flow in the CC in the same population of patients. Several groups have reported either normal or abnormal CC perfusion in diabetic eyes without DR by using spectral-domain OCTA (SD-OCTA).[@bib13]^--^[@bib16] However, one of the limitations of SD-OCTA is its shorter laser wavelength, which is more strongly scattered by the retinal pigment epithelium (RPE), resulting in significant sensitivity loss when imaging structures beneath the RPE, such as the CC.[@bib17] Swept-source OCTA (SS-OCTA), with a longer laser wavelength, has proven to be less affected by the RPE, allowing for more reliable visualization and detection of the CC.[@bib17]

This study is designed to investigate quantitative changes in the flow impairment of both the retina and CC in diabetic patients without retinopathy. In doing so, we employed a commercially available SS-OCTA instrument to collect the OCTA imaging data from enrolled patients for analyses.

Methods {#sec2}
=======

Participants {#sec2-1}
------------

In this study, patients with a diagnosis of DM without DR, as determined by clinical examination and fundus imaging, and age-matched patients without a history of DM in the Department of Ophthalmology at the University of Washington Eye Institute in Seattle between January 2017 and June 2018 were retrospectively analyzed. This study adhered to the tenets of the Declaration of Helsinki and was performed in accordance with the Health Insurance Portability and Accountability Act. Ethical approval was obtained from the Institutional Review Board of the University of Washington. All enrolled participants provided written informed consent. Exclusion criteria were eyes with known ocular diseases such as retinal or choroidal pathology, glaucoma, uveitis, a refractive error of less than --6.0 diopters, prior intraocular surgery, and systemic diseases that might affect the retina or choroid, such as uncontrolled hypertension, systemic lupus erythematosus, anemia, and leukemia. Clinical and demographic characteristics were obtained from electronic medical records.

Imaging and Image Processing {#sec2-2}
----------------------------

Study participants were imaged with SS-OCTA with a100-kHz A-line rate at 1060 nm (PLEX Elite 9000; Carl Zeiss Meditec, Inc, Dublin, CA, USA). A 6 × 6-mm (nominal) scan in the central macula was performed, consisting of 500 horizontal A-lines at 500 vertical locations with two repeated scans in each fixed location, resulting in a sampling spacing of 12 µm. The complex optical microangiography algorithm was used to obtain OCTA images.[@bib18] Retinal and CC layers were segmented using a validated semiautomated segmentation algorithm,[@bib19] and manual corrections were carried out as necessary to ensure accurate segmentation. The right eye was selected for analyses in the study unless gross eye movements or poor signal was noted. Images were excluded from the study if signal strength was less than seven as defined by the manufacturer or if there was severe motion artifact.

The retina was segmented into three depth-resolved layers (slabs) to better visualize vascular plexuses ([Fig. 1](#fig1){ref-type="fig"})[@bib20]^,^[@bib21]: the superficial retinal layer (SRL), which is a slab extending from the inner limiting membrane to the superficial portion of the inner plexiform layer (IPL); the intermediate retinal layer (IRL) extending from the deep portion of IPL to the superficial portion of the inner nuclear layer (INL); and the deep retinal layer (DRL) extending from the deep portion of INL to the outer plexiform layer. The retinal vascular plexuses of the nerve fiber layer, the ganglion cell layer, and the superficial portion of IPL were grouped together because these layers could not be accurately assessed in the foveal region.[@bib22] The vascular projection artifacts presented in the IRL and DRL slabs were removed using a previously published algorithm.[@bib23]

![En face OCTA images of three retinal layers: (**A**) SRL, (**B**) IRL, and (**C**) DRL.](iovs-61-3-50-f001){#fig1}

The vessel area density (VAD), vessel skeleton density (VSD), foveal avascular zone (FAZ) area, and nonperfusion area (NPA) were calculated from the en face angiograms using our previously described method.[@bib24]^--^[@bib26] The VAD, VSD, and NPA were calculated on three retinal layers in the rim with inner and outer ring diameters of 1.0 and 2.5 mm (R~1.5~, or parafovea) and the rim with inner and outer ring diameters of 2.5 and 5.0 mm (R~2.5~, or perifovea) ([Fig. 2](#fig2){ref-type="fig"}). The FAZ was automatically measured based on en face images of the whole retinal layer.

![Representative SS-OCTA 6 × 6-mm images of superficial retinal layer and regions used for quantification. (**A**, **F**) En face superficial retinal layer OCTA images where a 1.0-mm-diameter circle (*yellow*), a 2.5-mm-diameter circle (*red*), and a 5.0-mm-diameter circle (*yellow*) centered on the fovea were overlaid, which provides specific regions used for quantification: the rim with inner and outer ring diameters of 1.0 and 2.5 mm (R~1.5~, or parafovea), the rim with inner and outer ring diameters of 2.5 and 5.0 mm (R~2.5~, or perifovea), and the rim with inner and outer ring diameters of 1.0 and 5.0 mm (R~4.0~). (**B**, **G**) Corresponding VAD maps. (**C**, **H**) Corresponding vascular length density (VLD) maps. (**D**, **I**) Corresponding NPA maps. (**E**, **J**) Delineation of the FAZ. (**A--E**) Images are from a 61-year-old control patient. (**F--J**) Images are from a 61-year-old diabetic patient.](iovs-61-3-50-f002){#fig2}

The flow deficits (FDs) were measured by using our previously described method.[@bib27] The CC was defined as a slab from the outer boundary of Bruch\'s membrane (BrM) to approximately 20 µm below the outer boundary of BrM. The maximum projection was applied on the segmented volumes to generate the en face angiograms. Compensation for signal loss due to the overlying anatomy on CC angiograms was achieved by using the corresponding en face CC structural image, as previously described.[@bib27] The retinal vessel projection artifacts were removed before the identification of FDs in CC.[@bib23] The FDs were then segmented by using a global thresholding algorithm, followed by removal of the FDs with a size that is smaller than the normal intercapillary distance of 24 µm.[@bib28] The percentage of flow deficits (FD%) was calculated by the ratio between the total area of FDs and the whole area of the study region. The average size of the FDs was calculated as the total area of FDs divided by the number of FDs. Both measurements were conducted in D~1.0~, R~1.5~, R~2.5~, and the entire 5.0-mm disk (D~5.0~) ([Fig. 3](#fig3){ref-type="fig"}).

![Representative SS-OCTA 6 × 6-mm images of CC showing FDs and the regions used for quantification. (**A**, **E**) En face CC flow OCTA images after artifact removal and structural compensation. (**B**, **F**) Corresponding FDs (*green*) overlaid onto the CC image (*gray*). (**C**, **G**) Corresponding CC FD binary maps where the *white areas* indicate the FDs. (**D**, **H**) Showing regions on CC FD binary map for quantification where the marks are given for a 1.0-mm-diameter circle (*yellow*), a 2.5-mm-diameter circle (*red*), and a 5.0-mm-diameter circle (*yellow*) centered on the fovea, resulting in four regions used for quantification: the 5.0-mm disk (D~5.0~), 1.0-mm disk (D~1.0~), 1.5-mm inner rim from the 1.0-mm circle to the 2.5-mm circle (R~1.5~), and 2.5-mm outer rim from the 2.5-mm circle to the 5.0-mm circle (R~2.5~). (**A--H**) Images are from the same patients as in [Figure 2](#fig2){ref-type="fig"}. (**A--D**) Images are from a 61-year-old control patient. (**E--H**) Images are from a 61-year-old diabetic patient.](iovs-61-3-50-f003){#fig3}

Statistical Analysis {#sec2-3}
--------------------

All quantitative variables were reported as means, standard deviations (SDs), and ranges. Variable normality was inspected using histograms and the Shapiro-Wilk test. Student's *t-*test or Mann-Whitney *U* test was conducted to investigate differences in continuous variables between diabetics and controls based on variable normality. The statistical analyses were performed with IBM-SPSS software version 25.0 (IBM Corporation, Armonk, New York, NY, USA). A *P* value of less than 0.05 was considered statistically significant.

Results {#sec3}
=======

Sixteen eyes from 16 diabetic patients without clinically detectable retinopathy and 16 age-matched control eyes were included in this study. The populations did not show a significant difference in sex (with DM, 6 women and 10 men; without DM, 7 women and 9 men). The mean age of the participants was 61.6 ± 14.6 years (range, 22--78 years) in DM group and 61.8 ± 14.9 years (range, 22--80 years) in the control group. Mean duration of diabetes was 2.1 ± 1.2 years (range, 1--5 years). Mean glycosylated hemoglobin level in diabetic patients was 6.4% ± 0.9% (range, 5.0%--8.0%). Mean systolic blood pressure was 124.3 ± 5.1 mm Hg for controls and 126.4 ± 3.9 mm Hg for diabetics. Mean diastolic blood pressure was 73.4 ± 3.4 mm Hg for controls and 72.9 ± 7.1 mm Hg for diabetics. There was no significant difference in blood pressure measurements between the two groups (*P* = 0.138 and *P* = 1.000, respectively). In diabetic patients, there was one individual diagnosed with type 1 DM and the remaining individuals with type 2 DM.

Quantitative measurements of VAD, VSD, and NPA in the SRL, IRL, and DRL are shown in [Table 1](#tbl1){ref-type="table"}. There was no significant difference in these metrics between the controls and diabetes within all regions (R~1.5~ and R~2.5~, all *P* \> 0.05). While the mean area of FAZ in diabetic eyes (mean, 0.38 ± 0.15 mm^2^; range, 0.21--0.81 mm^2^) is slightly larger than that in control eyes (mean, 0.29 ± 0.15 mm^2^; range, 0.08--0.69 mm^2^), no significant difference was observed between them (*P* = 0.060).

###### 

Comparison of Vessel Area Density, Vessel Skeleton Density, and Nonperfusion Area Measurements in Three Retinal Layers Within Different Regions in Diabetic Eyes Without Retinopathy and Controls

                               Mean ± SD Vessel                            Mean ± SD Vessel                            Mean ± SD Nonperfusion                                                                                                              
  ---------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------
  Superficial retinal layer                                                                                                                                                                                                                                
   Controls                    0.44 ± 0.02                                 0.48 ± 0.02                                 0.12 ± 0.01                                 0.13 ± 0.01                                 0.54 ± 0.28                                 1.61 ± 0.46
                               (0.39 -- 0.49)                              (0.45 -- 0.52)                              (0.10 -- 0.13)                              (0.12 -- 0.14)                              (0.22 -- 1.24)                              (1.02 -- 2.76)
   Diabetics                   0.45 ± 0.02                                 0.49 ± 0.02                                 0.12 ± 0.01                                 0.13 ± 0.00                                 0.46 ± 0.23                                 1.67 ± 0.67
                               (0.42 -- 0.50)                              (0.46 -- 0.54)                              (0.12 -- 0.14)                              (0.12 -- 0.14)                              (0.08 -- 0.91)                              (0.76 -- 3.04)
   *P* value                   0.186[^\*^](#tb1fn1){ref-type="table-fn"}   0.190[^\*^](#tb1fn1){ref-type="table-fn"}   0.897[^†^](#tb1fn2){ref-type="table-fn"}    0.665[^\*^](#tb1fn1){ref-type="table-fn"}   0.590[^†^](#tb1fn2){ref-type="table-fn"}    0.753[^\*^](#tb1fn1){ref-type="table-fn"}
  Intermediate retinal layer                                                                                                                                                                                                                               
   Controls                    0.48 ± 0.02                                 0.49 ± 0.02                                 0.12 ± 0.00                                 0.13 ± 0.00                                 0.40 ± 0.14                                 1.82 ± 0.66
                               (0.45 -- 0.51)                              (0.46 -- 0.52)                              (0.12 -- 0.13)                              (0.12 -- 0.13)                              (0.14 -- 0.65)                              (1.04 -- 3.03)
   Diabetics                   0.50 ± 0.04                                 0.49 ± 0.03                                 0.13 ± 0.01                                 0.13 ± 0.01                                 0.31 ± 0.14                                 1.87 ± 0.49
                               (0.46 -- 0.63)                              (0.46 -- 0.56)                              (0.12 -- 0.15)                              (0.12 -- 0.15)                              (0.10 -- 0.65)                              (1.11 -- 2.99)
   *P* value                   0.138[^†^](#tb1fn2){ref-type="table-fn"}    0.752[^†^](#tb1fn2){ref-type="table-fn"}    0.051[^†^](#tb1fn2){ref-type="table-fn"}    1.000[^†^](#tb1fn2){ref-type="table-fn"}    0.065[^\*^](#tb1fn1){ref-type="table-fn"}   0.777[^\*^](#tb1fn1){ref-type="table-fn"}
  Deep retinal layer                                                                                                                                                                                                                                       
   Controls                    0.48 ± 0.03                                 0.50 ± 0.02                                 0.12 ± 0.01                                 0.13 ± 0.00                                 0.45 ± 0.23                                 0.84 ± 0.38
                               (0.44 -- 0.54)                              (0.47 -- 0.53)                              (0.11 -- 0.14)                              (0.12 -- 0.14)                              (0.11 -- 0.77)                              (0.29 -- 1.62)
   Diabetics                   0.52 ± 0.07                                 0.52 ± 0.03                                 0.13 ± 0.01                                 0.13 ± 0.01                                 0.41 ± 0.33                                 0.99 ± 0.54
                               (0.44 -- 0.75)                              (0.49 -- 0.62)                              (0.11 -- 0.15)                              (0.12 -- 0.15)                              (0.02 -- 1.21)                              (0.25 -- 2.48)
   *P* value                   0.110[^†^](#tb1fn2){ref-type="table-fn"}    0.138[^†^](#tb1fn2){ref-type="table-fn"}    0.135[^\*^](#tb1fn1){ref-type="table-fn"}   0.287[^†^](#tb1fn2){ref-type="table-fn"}    0.287[^†^](#tb1fn2){ref-type="table-fn"}    0.368[^\*^](#tb1fn1){ref-type="table-fn"}

Data are mean ± standard deviation unless otherwise indicated.

By *t-*test.

By Mann-Whitney *U* test.

The FD% and average size of the FDs within quantified regions in CC are displayed in [Table 2](#tbl2){ref-type="table"}. Mean FD% in CC was significantly increased in diabetic eyes compared with controls within D~1.0~ (23.72% vs. 16.06%; *P* = 0.011), R~1.5~ (16.60% vs. 12.15%; *P* = 0.003), R~2.5~ (11.04% vs. 8.29%; *P* = 0.018), and D~5.0~ (12.81% vs. 9.46%; *P* = 0.009) regions. Similar findings were observed on the average size of FDs. There was significantly increased FD size within D~1.0~ (3066.23 vs. 2088.34 µm^2^; *P* = 0.017), R~1.5~ (2147.86 vs. 1731.99 µm^2^; *P* = 0.009), R~2.5~ (1777.83 vs. 1497.02 µm^2^; *P* = 0.020), and D~5.0~ (2020.10 vs. 1651.23 µm^2^; *P* = 0.008) regions in diabetic eyes compared with controls.

###### 

Comparison of Percentage and Average Size of Flow Deficits Measurements in Choriocapillaris Within Different Regions in Diabetic Eyes Without Retinopathy and Controls

              Mean ± SD Percentage of Flow                Mean ± SD Average Size of Flow                                                                                                                                                                                                                                         
  ----------- ------------------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------
  Controls    16.06 ± 7.45                                12.15 ± 3.96                               8.29 ± 2.64                                 9.46 ± 2.95                                 2088.34 ± 768.86                            1731.99 ± 314.48                            1497.02 ± 238.92                            1651.23 ± 280.45
              (3.82 -- 28.89)                             (4.87 -- 19.88)                            (3.12 -- 12.87)                             (3.96 -- 14.93)                             (979.02 -- 3585.58)                         (1236.84 -- 2273.87)                        (1198.75 -- 1937.51)                        (1253.60 -- 2110.55)
  Diabetics   23.72 ± 8.59                                16.60 ± 4.59                               11.04 ± 3.51                                12.81 ± 3.75                                3066.23 ± 1346.99                           2147.86 ± 500.09                            1777.83 ± 388.12                            2020.10 ± 441.58
              (0.88 -- 36.82)                             (3.90 -- 24.90)                            (2.74 -- 16.61)                             (2.92 -- 18.56)                             (778.20 -- 6033.12)                         (1136.27 -- 3220.87)                        (1048.08 -- 2602.22)                        (1080.72 -- 2779.87)
  *P* value   0.011[^\*^](#tb2fn1){ref-type="table-fn"}   0.003[^†^](#tb2fn2){ref-type="table-fn"}   0.018[^\*^](#tb2fn1){ref-type="table-fn"}   0.009[^\*^](#tb2fn1){ref-type="table-fn"}   0.017[^\*^](#tb2fn1){ref-type="table-fn"}   0.009[^\*^](#tb2fn1){ref-type="table-fn"}   0.020[^\*^](#tb2fn1){ref-type="table-fn"}   0.008[^\*^](#tb2fn1){ref-type="table-fn"}

Data are mean ± standard deviation unless otherwise indicated.

By *t-*test.

By Mann-Whitney *U* test.

Discussion {#sec4}
==========

The current study used a commercially available SS-OCTA to investigate the retinal and CC blood perfusion in diabetic eyes without clinically visible DR and compared their quantitative indices with those of nondiabetic controls. The diabetic eyes included in this study were from patients recently diagnosed with DM (between 1 and 5 years), and the quantitative assessments demonstrated that the CC flow reduction may precede the retinal flow changes in the macula. This finding may suggest that flow deficits in the choriocapillaris might be an earlier preclinical marker of microvascular dysfunction than retinal microvasculature in diabetic eye disease.

Using OCTA to assess the retinal vascular density in diabetic eyes without clinically visible DR, researchers have drawn mixed conclusions. For example, Dimitrova et al.[@bib16] and Hwang et al.[@bib29] showed significantly reduced parafoveal VAD in both the superficial and deep retinal capillary plexuses in diabetic eyes without retinopathy compared to controls, while Simonett et al.[@bib30] and Carnevali et al.[@bib15] reported significantly reduced parafoveal VAD in the deep but not in the superficial plexus in diabetic eyes without retinopathy. In contrast, other groups demonstrated that no significant differences were found in the superficial, deep, or whole parafoveal VAD between the two groups.[@bib13]^,^[@bib14] Compared with VAD, VSD is a more sensitive metric to measure perfusion changes at the capillary level.[@bib24] However, VSD has not been compared between diabetic patients without retinopathy and nondiabetic controls. Although OCT and histology studies have confirmed the trilaminar capillary layout in the parafovea and perifovea,[@bib20]^,^[@bib21]^,^[@bib31] most of the published studies investigating vessel density separated the retinal vascular system into two major plexuses. Moreover, recent studies also showed that additional segmentation and evaluation of the intermediate retinal layer from the superficial and deep retinal layers may enhance the ability of OCTA to detect early microvascular changes in diabetic eyes.[@bib29]^,^[@bib32]^,^[@bib33] In this study, VAD and VSD were measured on the SRL, IRL, and DRL using our validated semiautomated segmentation algorithm. Our study showed that no significant difference was found in VSD or VAD in diabetic eyes without retinopathy compared to controls within the three vascular plexuses for a 6 × 6-mm scanning protocol.

The FAZ area assessed by OCTA has also been well investigated in diabetic eyes without retinopathy. Some groups reported a small but significant enlargement of the FAZ area in diabetic eyes without retinopathy compared to controls,[@bib16]^,^[@bib34] while others reported no significant difference of FAZ between the two groups.[@bib13]^--^[@bib15]^,^[@bib35]^--^[@bib37] All of the aforementioned measurements were conducted using the built-in default settings of commercial systems with automatic segmentation into two slabs (superficial and deep). Because of inherent errors in automatic segmentation of the superficial and deep capillary plexuses within the central fovea, FAZ measurements using default settings are likely to be biased.[@bib38] We measured the FAZ area by utilizing the full-thickness retinal slab at the edge of the FAZ where the retinal vascular plexuses merge,[@bib22] rather than attempting to divide it artificially. Our study showed no statistically significant difference in the FAZ area between the two groups, which was consistent with recent reports.[@bib29]^,^[@bib36] However, another report found a small enlargement of the FAZ measured on the full-thickness slab in diabetic eyes without retinopathy.[@bib39] Further studies with larger sample sizes are needed to evaluate whether FAZ measurements would be a useful diagnostic tool for early diabetic microvascular dysfunction.

Retinal nonperfusion area (NPA) measurements were reported as a sensitive OCTA quantitative metric and could distinguish diabetic eyes without retinopathy from normal eyes.[@bib29]^,^[@bib36] We also conducted a detailed investigation into the NPA; however, in our study, no statistical difference of the NPA was observed in the parafoveal or perifoveal region between the two groups in different retinal layers. One possibility for the discrepancy in the results is that in contrast to the earlier study, our diabetic cohort had a short duration from diagnosis of DM (2.1 ± 1.2 years), which may have allowed us to study the microvascular changes in diabetic eyes at a very early stage. Furthermore, although the NPA was reported to be less age dependent,[@bib40] we nevertheless selected age-matched individuals as controls in this study since prior investigations have shown that vascular density,[@bib41]^--^[@bib43] FAZ size,[@bib41]^,^[@bib43] and CC FDs tended to be influenced by age.[@bib44]^,^[@bib45]

Several groups also investigated CC perfusion in diabetic eyes. Using an investigational SS-OCT system, Choi et al.[@bib46] described focal or diffuse CC flow impairment in diabetic eyes without quantitative assessments. Nesper et al.[@bib13] reported increased percent area of nonperfusion in CC in a 3 × 3-mm angiogram in diabetic eyes without retinopathy using a commercially available SD-OCT system. On the other hand, other groups reported no significant difference in CC vessel density between diabetic eyes without retinopathy and normal controls with SD-OCTA.[@bib14]^--^[@bib16] However, the vessel density metric may not be a good choice for CC quantification. As we know, CC vasculature is extremely dense in the posterior pole with small intercapillary distances (5--20 µm) that are smaller than the OCT system\'s lateral resolution (15--20 µm)[@bib47]; therefore, individual capillaries of CC cannot be clearly resolved with current commercial OCT systems. Instead of quantifying the CC vasculature directly, many researchers have chosen flow deficits to analyze CC perfusion.[@bib12]^,^[@bib44]^,^[@bib45] The CC FD represents the area where there is a lack of CC flow or CC flow below the detectable threshold of the OCT system. To improve the robust assessment of the CC FDs, we segmented FDs with a size larger than normal intercapillary spacing (24 μm in diameter) for quantification, which is within the capability of the OCT system to resolve.[@bib28] Moreover, we quantitated and compared the CC FDs in different macular regions since the CC FDs presented regional distributions in the macula.[@bib44]^,^[@bib45] We observed significantly increased FD% and enlarged average size of FDs in CC in diabetic eyes compared with controls within all quantified regions.

Vascular abnormalities in the choriocapillaris have also been demonstrated in diabetic eyes without retinopathy in histopathologic studies. Using alkaline phosphatase activity as a marker for viable CC endothelial cells, McLeod and Lutty[@bib48] found that CC dropout was generally much more pronounced and involved larger areas in postmortem subjects with diabetes even without DR than those without diabetes. Interestingly, in a mouse model of DM, reduced choroidal perfusion was noted to occur prior to alterations of retinal perfusion and visual function.[@bib49] Impaired visual function preceding clinically visible DR has also been observed in some population-based studies.[@bib50]^,^[@bib51] In the present study, we demonstrated with noninvasive SS-OCTA that CC perfusion reduction may precede retinal vascular changes in the macula of diabetic eyes. Although the outer retina receives most of its blood supply from the CC,[@bib52] whether reduced perfusion contributes to abnormal visual function in diabetic patients before overt retinopathy still requires further investigation.

We acknowledge several limitations in this study. First, our study included a relatively small number of patients. This was mainly related to the strict exclusion criteria we employed. Larger cohort studies are necessary to confirm these preliminary findings. Second, this is a cross-sectional analysis with a short duration of diabetes. With the increase of duration, choroidal and retinal microvascular alterations may be more obvious and present different characteristics. Further longitudinal studies are needed to elucidate these microvascular alterations over time with the progression of diabetes. Third, no significant changes in retinal perfusion metrics were observed between the two groups. However, this does not necessarily mean that early retinal vascular alterations are not actually present. The development of more sensitive OCTA metrics may help to detect retinal perfusion alterations in early diabetes. Fourth, imaging of the deep large choroidal vessels may also provide additional information on the pathogenesis and progression of diabetic eye disease, which warrants a proper investigation. Lastly, we did not correct image magnification in lateral measurements due to the variation of axial length.[@bib53] The magnification variation may affect the ability of the quantification metrics of FAZ, NPA, and CC FD sizes, although it has a negligible effect on the density or percentage measurements (e.g., VAD, VSD, and CC FD%). In the current study, only the patients with a refraction error less myopic than --6.0 diopters were included for the analyses. This inclusion criterion would limit the magnification variation to a relatively small range. This study was retrospective in its nature, and axial length measurements were not available for all the patients. Nevertheless, we ran a test on the FAZ, NPA, and mean size of FDs by considering the magnification variation and assuming the axial length artificially at the extreme cases of 26.4 mm (--6.0 diopters) and found that this did not change our final conclusions. However, we would suggest in future larger cohort and longitudinal studies that this magnification factor is considered for more accurate analyses to draw more definitive conclusions, particularly in the cases of myopic/hyperopic eyes.

Conclusions {#sec5}
===========

Noninvasive, in vivo SS-OCTA imaging revealed that perfusion of the choriocapillaris is significantly decreased in diabetic patients without retinopathy compared with age-matched nondiabetic controls. This decrease in CC perfusion was noted despite an absence of macular retinal vessel parameter changes. Decreased CC perfusion in the macula may be an early indicator of otherwise clinically undetectable diabetic vasculopathy. Further larger longitudinal studies are needed to confirm these findings and elucidate microvascular alterations over time in diabetic eyes.
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